Ontology highlight
ABSTRACT:
SUBMITTER: Cummings J
PROVIDER: S-EPMC5651348 | biostudies-literature | 2016 Nov
REPOSITORIES: biostudies-literature
Cummings Jeffrey J Morstorf Travis T Lee Garam G
Alzheimer's & dementia (New York, N. Y.) 20160817 4
<h4>Background</h4>Alzheimer's disease (AD) is growing in frequency and new therapies are urgently needed.<h4>Methods</h4>We assessed clinicaltrials.gov (accessed 1-4-2016) to determine the number and characteristics of trials in phase I, phase II, and phase III for treatment of AD.<h4>Results</h4>There are currently 24 agents in 36 trials in phase III of AD drug development. Seven of these 24 agents are symptomatic cognitive-enhancing compounds, and 17 are disease-modifying treatments (DMTs). M ...[more]